NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN
Post# of 157
(Total Views: 112)
Posted On: 02/27/2024 4:12:40 PM
NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function,” a recent article reads. The article discusses CNM-Au8 development pathways, which have included: a Phase 2 VISIONARY trial in MS; two Phase 2 brain imaging studies, REPAIR-MS and REPAIR-PD, in participants with MS and PD; RESCUE-ALS, a nine-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in early-stage ALS participants; and a HEALEY-ALS Platform trial, a six-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in participants with ALS. “During 2024, Clene will work with the U.S. FDA to consider the strength of Clene’s data while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function,” a recent article reads. The article discusses CNM-Au8 development pathways, which have included: a Phase 2 VISIONARY trial in MS; two Phase 2 brain imaging studies, REPAIR-MS and REPAIR-PD, in participants with MS and PD; RESCUE-ALS, a nine-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in early-stage ALS participants; and a HEALEY-ALS Platform trial, a six-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in participants with ALS. “During 2024, Clene will work with the U.S. FDA to consider the strength of Clene’s data while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)